Using a blood telomere test to help diagnose lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multicentre, open‑label case‑control clinical performance investigation collects blood samples from adults 45 and older at several hospitals in Spain to measure telomere-based biomarkers. Participants include treatment‑naive, pathologically confirmed lung cancer patients and two control groups: high‑risk smokers and low‑risk screened individuals. Telomere analysis in the lab will be used to build a predictive model that classifies results as positive or negative for the probability of lung cancer. The primary aim is to see if the telomere test can distinguish cancer cases from controls and serve as a noninvasive diagnostic aid.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Case Group:

* Person aged 45 years or older at the time of signing the consent form.
* Person with a current anatomopathologically confirmed diagnosis of small-cell or non-small cell lung cancer.
* Not having received any oncological treatment prior to sample collection (surgery, radiotherapy, or systemic treatment with chemotherapy or immunotherapy).

Control Group:

Cohort A (High risk controls):

* Person aged 45 years or older at the time of signing the consent form.
* High risk of lung cancer, defined as having a smoking history of at least 20 pack-year and currently smoking or having quit within the past 15 years.
* No diagnosis or suspicion of lung cancer. Asymptomatic individuals who have undergone a chest computed tomography (CT) scan for lung cancer screening within the 12 months prior to signing the informed consent and as part of routine clinical practice, with a LUNG-RADS score of 3 or lower, will be included.

Cohort B (Low-risk controls):

* Person aged 45 years or older at the time of signing the consent form.
* Without high risk of lung cancer according to the criteria defined in cohort A.
* No diagnosis or suspicion of lung cancer.

Exclusion Criteria:

* History of any malignant neoplasm, except for subjects with tumors in localized stages who have undergone radical treatment and have been disease-free for at least five years.
* Patient diagnosed with lung cancer who has already started oncological treatment before sample collection.
* Patient who has undergone a biopsy or any invasive procedure or minor surgery less than 48 hours ago.
* Patient who has undergone major surgery less than 7 days ago.
* Patient with severe chronic kidney disease, defined as a glomerular filtration rate below 15 ml/min.
* Patient with severe liver disease, defined as Child-Pugh C.
* Active infection, or treated less than 4 weeks ago.
* Vulnerable population, for example, minors, prisoners, pregnant women, adults physically or mentally incapable of giving consent.

Where it's running

• Hospital General Universitario de Elche
  Elche, Alicante, Spain Recruiting
• Hospital del Mar
  Barcelona, Barcelona, Spain Recruiting
• Institut Catalá D'Oncologia Badalona (ICO)
  Barcelona, Barcelona, Spain Recruiting
• Hospital Universitario Marqués de Valdecilla
  Santander, Cantabria, Spain Recruiting
• Clínica Universidad de Navarra
  Madrid, Madrid, Spain Recruiting
• HM Sanchinarro/CIOCC
  Madrid, Madrid, Spain Recruiting

Study contacts

• Study coordinator: Antonio Cubillo, MD
• Email: acubillo@hmhospitales.com
• Phone: 917 56 79 97

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Boosting lung cancer screening for patients seen in the emergency department

  This project will test whether giving eligible emergency department patients a facilitated referral plus text reminders helps more people get lung cancer screening.

  Recruiting University of Rochester · Rochester, New York · NCT07287085

• Risk-based lung cancer screening in COPD patients using ML and clinical models

  This study tests whether a PLCOm2012 risk model plus a machine learning model can spot COPD patients at high risk for lung cancer to see if they benefit from low-dose CT screening.

  Recruiting Vejle Hospital · Vejle, Region Syddanmark · NCT07848815

• Morningness vs. eveningness and how quickly healthy adults recover after submaximal exercise

  This study tests whether people who prefer morning or evening are linked to how quickly healthy adults recover after a light-to-moderate workout.

  Recruiting Saglik Bilimleri Universitesi · Istanbul · NCT07833956

• AI-Personalized Discharge Education After Lung Cancer Surgery

  This study tests whether an AI-generated, personalized discharge guide helps patients recover better after lung cancer surgery compared with standard discharge education.

  Recruiting Xiamen University · Siping, Jilin · NCT07827183

• Next Generation Delivery System (NGDS) for SBRT in thorax and upper abdomen

  A study tests a new machine to deliver SBRT more quickly and comfortably for adults with thoracic or upper abdominal cancers.

  Recruiting at 2 sites Varian, a Siemens Healthineers Company · St Louis, Missouri and 1 other locations · NCT07824583

• Low-Intensity Endurance Exercise to Help Lung Cancer-Related Fatigue

  This trial tests whether light, regular endurance exercise can help reduce fatigue and improve quality of life for people with lung cancer in addition to their usual care.

  Recruiting Taipei Medical University · Taipei · NCT07806682

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.